FAMPRIDINE EG LP 10 mg, extended-release tablet 56 tablets
Active ingredients: Dalfampridine
Commercialized according to BDPMDispensing in France: Prescription only
Extended-release tablet56 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- FAMPRIDINE EG LP 10 mg, comprimé à libération prolongée
- Pharmaceutical form
- comprimé à libération prolongée
- Route of administration
- orale
- Presentation description
- 56 plaquette(s) prédécoupées aluminium de 1 comprimé(s)
- Marketing authorisation holder
- EG LABO - LABORATOIRES EUROGENERICS
- Reimbursement according to BDPM
- 15%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 26 Aug 2026
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
60185105CIP73025896CIP133400930258965Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| FAMPRIDINEcomprimé | 10 mg · un comprimé | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.